A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Clinical trial NCT04465890 · COMPLETED

Trial details

NCT number: NCT04465890
Sponsor: Ascletis Pharmaceuticals Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Hepatitis b

Start date: 2020-07-17
Primary completion: 2024-08-09
Enrollment: 207

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.